Latest Trials
Latest News
FAQ
Pharmaceutical Companies
Pharma Details
Eisbach Bio GmbH
🇩🇪
Germany
Country
🇩🇪
Germany
Ownership
Holding
Established
2019-01-01
Employees
11
Market Cap
-
Website
https://www.eisbach.bio
Clinical Trials
Related News
EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors
Phase 1
Recruiting
Conditions
Advanced Solid Tumor
HRR Deficiency
Homologous Recombination Deficiency
Interventions
Drug: EIS-12656
Drug: Olaparib
Drug: Trastuzumab deruxtecan
Subscribe
First Posted Date
2024-07-29
Last Posted Date
2024-08-28
Lead Sponsor
Eisbach Bio GmbH
Target Recruit Count
144
Registration Number
NCT06525298
Locations
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Subscribe
Prev
1
Next
© Copyright 2024. All Rights Reserved by MedPath
Home
Terms & Conditions
Privacy Policy